Thymulin Zinc Dependence: The 1:1 Zinc-Bound Active Form

The gist

Thymulin zinc dependence is the simplest, strangest thing about this hormone: it is a light switch. Without a zinc atom attached, the peptide is inert — chemists call this the apopeptide. Attach exactly one zinc atom per molecule, and it folds into the active shape and starts working on T cells (the immune system's trained defender cells). One zinc, one peptide, a 1:1 ratio. Strip the zinc out with a chelator and activity vanishes; add zinc back and it returns. That on-off behavior, found in 1982, is why thymulin's effects are tangled up with the body's zinc status.

Why does thymulin need zinc to work?

Zinc binding gives thymulin a specific three-dimensional conformation required for activity. A free nonapeptide is a floppy chain; the bound zinc ion pins it into the one shape its receptor recognizes. In the foundational 1982 experiment, treating the peptide with the chelator Chelex 100 abolished its biological activity in the rosette assay; zinc salts restored it, with an optimal 1:1 metal-to-peptide molar ratio ^[1]. Other metals could partly substitute, but zinc was the clear optimum ^[1].

Later work resolved the zinc-bound form's specific 3D conformation by NMR, which is the direct structural confirmation of the conformational hypothesis ^[2]. The distinction worth holding onto is that zinc here is not a cofactor the peptide borrows transiently during a reaction — it is the structural key that builds the active shape, and without it there is no active molecule, only the inert apopeptide ^[1]. That is why every downstream claim about thymulin carries an implicit "with its zinc": the zinc-free form simply does not do these things ^[12].

Thymulin and Serum Thymic Factor (FTS)

Serum thymic factor — FTS, from the French "facteur thymique serique" — is the original name for the peptide ^[1]. The two-name situation is not redundancy; it encodes the discovery. Researchers proposed "thymulin" specifically for the zinc-bound, biologically active form (FTS-Zn), reserving the older FTS name for the parent peptide, whose zinc-free version is the inactive apopeptide ^[1]. So when older literature says FTS and newer literature says thymulin, they are describing the same molecule at different points in the story — and the zinc is what separates the active form from the inert one ^[12].

The naming carries a practical warning. Because the active and inactive forms share a peptide backbone, a measurement of "how much peptide is present" is not a measurement of "how much active hormone is present." The 1982 work made exactly that distinction operational, defining two forms — a zinc-free, biologically inactive one and a zinc-bound, active one — and showing you could move between them by adding or stripping the metal ^[1]. This is why the field measures thymulin by biological activity in an assay rather than by peptide quantity alone, and why a vial of the peptide is not, by itself, a vial of active thymulin without the zinc the molecule requires ^[1][12].

The Role of Zinc in Thymulin Activity

The zinc thymulin relationship runs deeper than a single binding event — it makes serum thymulin activity a readout of zinc status. In a 1994 synthesis, serum thymulin activity falls with zinc deficiency and is corrected by zinc supplementation in animals and humans, positioning thymulin activity as a sensitive indicator of zinc availability ^[2].

The human evidence is direct. In three models of mild human zinc deficiency — two dietary-restriction volunteers and twelve adults with and without sickle-cell anemia — serum thymulin activity was decreased despite normal plasma zinc, and was corrected by both in-vivo and in-vitro zinc supplementation, alongside reversible shifts in T-cell subsets and IL-2 (interleukin-2) activity ^[3]. The distinction that result forces is subtle and important: normal plasma zinc did not guarantee active thymulin. What mattered was the zinc actually available to the peptide, not the total in circulation ^[3].

The same theme recurs in disease. In cervical-carcinoma patients, active thymulin was reduced despite normal plasma zinc — attributed to elevated alpha-2-macroglobulin, a zinc-binding protein, competing for the metal — and that reduction correlated with decreased natural-killer-cell activity and IL-2 production ^[13]. Here a competing protein, rather than dietary lack, lowered the zinc available to thymulin, and immune function tracked the change. The lesson across these studies is consistent: thymulin's activity is only as good as its zinc supply, and several different mechanisms can constrain that supply ^[2][13].

What is the amino acid sequence of thymulin?

Thymulin is a nonapeptide with the sequence pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (also written <Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn), molecular formula C33H54N12O15 ^[1]. Zinc binds this peptide in a 1:1 ratio to produce the active conformation ^[1]. It is produced exclusively by thymic epithelial cells ^[4].

Is thymulin the same as serum thymic factor (FTS)?

Serum thymic factor (FTS, "facteur thymique serique") is the original name for the peptide ^[1]. Researchers proposed the name "thymulin" specifically for the zinc-bound, biologically active form (FTS-Zn); the zinc-free form is the inactive apopeptide ^[1]. Same molecule, two names, with zinc as the dividing line.

Does thymulin have anti-aging effects?

Circulating thymulin declines with age, partly because of reduced zinc saturation of the peptide; in aged mice, zinc repletion restored thymic function and thymulin activity ^[14]. One proposed mechanism is that elevated zinc-bound metallothionein in aging tissue sequesters zinc away from thymulin ^[14]. This is a zinc-and-immunosenescence research finding, not a demonstrated anti-aging effect in humans.